The management of axial spondyloarthritis with cutting-edge therapies: advancements and innovations

Giuseppe Lopalco,Andrea Cito,Vincenzo Venerito,Florenzo Iannone,Fabian Proft
DOI: https://doi.org/10.1080/14712598.2024.2389987
2024-08-30
Expert Opinion on Biological Therapy
Abstract:Introduction Axial involvement in spondyloarthritis has significantly evolved from the original 1984 New York criteria for ankylosing spondylitis, leading to an improved understanding of axial spondyloarthritis (axSpA) as a disease continuum encompassing non- radiographic axSpA (nr-axSpA) and radiographic axSpA (r-axSpA). A clear definition for early axSpA has been established, underscoring the need for early intervention with biological and targeted synthetic drugs to mitigate pain, reduce functional impairment, and prevent radiographic progression.
medicine, research & experimental,biotechnology & applied microbiology
What problem does this paper attempt to address?